title: [Clinical outcomes and prognostic factors in limited-stage small cell lung cancer: a single institution experience].
abstract: OBJECTIVE
  To evaluate the effect of comprehensive treatment and examine the impact of clinical factors on the survival outcome of limited-stage small cell lung cancer.
  
  
  METHODS
  The clinical records of 335 patients with limited-stage small cell lung cancer treated in the Cancer Hospital of Chinese Academy of Medical Sciences between January 1996 and December 2006 were analyzed retrospectively in this study. Kaplan-Meier method was used for survival analysis, and log-rank test and Cox regression were used for univariate and multivariate analyses of prognostic factors.
  
  
  RESULTS
  The median follow-up time was 54 months for all patients, the median survival time was 23.8 months, and progression-free survival was 12.5 months. The 2-, 3-, and 5-year overall survival rates were 47.3%, 32.9%, and 22.9%, respectively. The acute toxicity during comprehensive treatment was tolerable. The incidence of ≥grade 3 hematological toxicity, ≥grade 3 gastrointestinal toxicity, ≥grade 2 radiation pneumonitis and ≥grade 2 acute esophagitis were 37.0%, 14.9%, 11.0%, and 38.8%, respectively. The univariate analysis showed that KPS<80, smoking and high LDH level significantly reduced the overall survival time in patients with limited-stage SCLC. The multivariate analysis showed that KPS and weight loss were independent factors affecting the prognosis for the limited stage SCLC patients (P<0.05 for all).
  
  
  CONCLUSIONS
  Sequential chemoradiotherapy can be safely and effectively performed in limited-stage small cell lung cancer. Krnofsky performance status and weight loss are independent prognostic factors for the overall survival of LS-SCLC.
authors.affiliation: Department of Radiation Oncology, Cancer Hospital (Institute), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
authors.forename: Wenjue
authors.initials: W
authors.lastname: Zhang
authors.forename: Hui
authors.initials: H
authors.lastname: Zhu
authors.forename: Zongmei
authors.initials: Z
authors.lastname: Zhou
authors.forename: Qinfu
authors.initials: Q
authors.lastname: Feng
authors.forename: Dongfu
authors.initials: D
authors.lastname: Chen
authors.forename: Hongxing
authors.initials: H
authors.lastname: Zhang
authors.forename: Zefen
authors.initials: Z
authors.lastname: Xiao
authors.affiliation: Email: wlhwq@yahoo.com.
authors.forename: Lühua
authors.initials: L
authors.lastname: Wang
mesh_terms: D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D004941:Esophagitis; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis* / Q000453:epidemiology / Q000473:pathology; D016019:Survival Analysis; D015996:Survival Rate